Clinic Roundup
Lithera Inc., of San Diego, said the first patient was treated with LIPO-202 (salmeterol xinafoate for injection) in its 500-patient Phase IIb RESET trial. LIPO-202 is Lithera's lead candidate designed to produce localized reduction of subcutaneous fat.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.